How acute promyclocytic leukaemia revived arsenic

Nature Reviews Cancer

Volumn 2, Issue 9, 2002, Pages 705-713

  Zhu, Jun ^a,b   Chen, Zhu ^b   Lallemand Breitenbach, Valérie ^a   De Thé, Hugues ^a  

^a CNRS   (France)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CASPASE; CELL NUCLEUS RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RETINOIC ACID; NUCLEAR PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PML PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CELL LINE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; EUROPE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; REVIEW; TELOMERE; ANIMAL; CELL DIFFERENTIATION; CHINA; GENE EXPRESSION REGULATION; GENETICS; HISTORY; METABOLISM; PATHOLOGY;

ANIMALS; ARSENICALS; CELL DIFFERENTIATION; CHINA; EUROPE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTORY, 15TH CENTURY; HISTORY, 16TH CENTURY; HISTORY, 18TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OXIDES; RECEPTORS, RETINOIC ACID; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0036715589     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc887     Document Type: Review

References (110)

1. Micca, G. Arsenic, or rather, arsenious anhydride, the preferred poison of the Borgias. Minerva Med. 60, IX-XI (1969).
2. Keynes, M. Did Napoleon die from arsenical poisoning? Lancet 344, 276 (1994).
3. Alpert, M. A touch of poison. Sci. Am. 284, 20-21 (2001).
4. Huff, J., Chan, P. & Nyska, A. Is the human carcinogen arsenic carcinogenic to laboratory animals? Toxicol. Sci. 55, 17-23 (2000).
5. Bode, A. M. & Dong, Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit. Rev. Oncol. Hematol. 42, 5-24 (2002).
6. Haller J. S. Therapeutic mule: the use of arsenic in the nineteenth century materia medica. Pharm. Hist. 17, 87-100 (1975).
7. Kwong, Y. L. & Todd, D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 89, 3487-3488 (1997).
8. Waxman, S. & Anderson, K. C. History of the development of arsenic derivatives in cancer therapy. Oncologist 6, 3-10 (2001).
9. 3 therapy in APL.
10. Zhang, P. et al. Treatment of 72 cases of acute promyelocytic leukemia with intravenous arsenic trioxide. Chin. J. Hematol 17, 58-62 (1996).
11. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α/PML proteins. Blood 88, 1052-1061 (1996).
12. 3 specifically in APL cells. Greater doses induce apoptosis, as in various non-APL cell lines.
13. Espinoza, E., Mann, M. & Bleasdell, B. Arsenic and mercury in traditional chinese herbal balls. N. Engl. J. Med. 333, 803-804 (1995).
14. Soignet, S. L. et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339, 1341-1348 (1998).
15. Lu, D. P. et al. Tetra-arsenic tetra sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 99, 3136-3143 (2002).
16. Warrell, R., de Thé, H., Wang, Z. & Degos, L. Acute promyelocytic leukemia. N. Engl. J. Med. 329, 177-189 (1993).
17. de Thé, H. et al. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor-α gene to a novel transcribed locus. Nature 347, 558-561 (1990).
18. Borrow, J., Goddart. A., Sheer, D. & Solomon, E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 249, 1577-1580 (1990).
19. Huang, M. et al. Use of all trans retinoic acid in the treatment of acute promyelocytic leukaemia. Blood 72, 567-572 (1988). First demonstration that retinoic acid induces the differentiation of acute promyelocytic leukaemia cells in vivo, resulting in complete remission in patients with this cancer.
20. Rochette-Egly, C. et al. Stimulation of RARα activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell 90, 97-107 (1997).
21. de Thé, H., Marchio, A., Tiollais, P. & Dejean, A. Differential expression and ligand regulation of the retinioc acid receptor α and β genes. EMBO J. 8, 429-433 (1989).
22. Zhu, J. et al. Lineage restriction of the RARα gene expression in myeloid differentiation. Blood 98, 2563-2567 (2001).
23. Johnson, B. S., Mueller, L., Si, J. & Collins, S. J. The cytokines IL-3 and GM-CSF regulate the transcriptional activity of retinoic acid receptors in different in vitro models of myeloid differentiation. Blood 99, 746-753 (2002).
24. -/- mice.
25. de Thé, H. et al. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66, 675-684 (1991).
26. Kakizuka, A. et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 66, 663-674 (1991).
27. Grignani, F. et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 391, 815-818 (1998).
28. Lin, R. J. et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia Nature 391, 811-814 (1998).
29. He, L.-Z. et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nature Genet 18, 126-135 (1998).
30. Hong, S. H. et al. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor-α (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 94, 9028-9033 (1997).
31. Lin, P. & Evans, R. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell 5, 821-830 (2000).
32. Minucci, S. et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell. 5, 811-820 (2000).
33. Chen, Z. et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation in acute promyelocytic leukemia. EMBO J. 12, 1161-1167 (1993).
34. Gu, B. W. et al. Variant-type PML-RARα fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RARα gene and identification of a new clinical subtype resistant to retinoic acid therapy. Proc. Natl Acad. Sci. USA 99, 7640-7645 (2002).
35. Slack, J. L. et al. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARα isoform: results from Intergroup protocol 0129. Blood 95, 398-403 (2000).
36. Perez, A. et al. PML-RAR homodimers: distinct binding properties and heteromeric interactions with RXR. EMBO J. 12, 3171-3182 (1993).
37. Jansen, J. H. et al. Multimeric complexes of the PML-retinoic acid receptor-α fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways. Proc. Natl Acad. Sci. USA 92, 7401-7405 (1995).
38. Kogan, S. C. et al. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor-α chimeric protein (PML-RARα) to block neutrophil differentiation and initiate acute leukemia. J. Exp. Med. 193, 531-544 (2001).
39. Le Beau, M. M., Bitts, S., Davis, E. M. & Kogan, S. C. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood 99, 2985-2991 (2002).
40. Wang. Z.-G et al. PML is essential for multiple apoptotic pathways. Nature Genet. 20, 266-272 (1998). Cells devoid of the promyelocytic leukaemia gene product are apoptosis resistant and their myeloid differentiation is impaired.
41. Wang, Z. G. et al. Role of PML in cell growth and the retinoic acid pathway. Science 279, 1547-1551 (1998).
42. Quignon, F. et al. PML induces a caspase-independent cell death process. Nature Genet. 20, 259-265 (1998).
43. Gottifredi, V. & Prives, C. p53 and PML: new partners in tumor suppression. Trends Cell. Biol. 11, 184-187 (2001).
44. Mu, Z. M. et al. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol. Cell. Biol. 14, 6858-6867 (1994).
45. Koken, M. H. M. et al. The PML growth-suppressor has an altered expression in human oncogenesis Oncogene 10, 1315-1324 (1995).
46. Terris, B. et al. PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res. 55, 1590-1597 (1995).
47. Daniel, M.-T. et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82, 1858-1867 (1993).
48. Koken, M. H. M. et al. The t(15;17) translocation alters a nuclear body in a RA-reversible fashion. EMBO J. 13, 1073-1083 (1994).
49. Weis, K. et al. Retinoic acid regulates aberrant nuclear localization of PML/RARα in acute promyelocytic leukemia cells Cell 76, 345-356 (1994).
50. Dyck, J. A. et al. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76, 333-343 (1994). References 47-50 were the first to demonstrate the retinoic acid-reversible abnormal localization of the promyelocytic leukaemia gene product in acute promyelocytic leukaemia cells.
51. Grignani, F. et al. The acute promyelocytic leukemia specific PML/RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74, 423-431 (1993).
52. Yoshida, H. et al. Accelerated degradation of PML-retinoic acid receptor-α (PML-RARα) oncoprotein by all-trans retinoic acid in acute promyelocytic leukemia. Possible role of the proteasome pathway. Cancer Res. 56, 2945-2948 (1996).
53. Raelson, J. V. et al. The PML-RARα oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 88, 2826-2832 (1996).
54. Zhu, J. et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptorα (RARα) and oncogenic RARα fusion proteins. Proc. Natl Acad. Sci. USA 96, 14807-14812 (1999).
55. Zhu, J. et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 94, 3978-3983 (1997). Arsenic degrades PML-RARα by targeting its PML moiety.
56. vom Baur, E. et al. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcdptional intermediary factors mSUG1 and TIF1. EMBO J. 15, 110-124 (1996).
57. Thomas, D. & Tyers, M. Transcriptional regulation: Kamikaze activators. Curr Biol. 10, R341-R343 (2000).
58. Altucci, L. et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nature Med. 7, 680-686 (2001).
59. Liu, T. X. et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 96, 1496-1504 (2000).
60. Muto, A. et al. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. Leukemia 15, 1176-1184 (2001).
61. Zhu, Q. et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 99, 1014-1022 (2002).
62. Germolec, D. R. et al. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am. J. Pathol. 153, 1775-1785 (1998).
63. 3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 14, 431-438 (2000).
64. 3.
65. Camacho, L. H. et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J. Clin. Oncol. 18, 2620-2625 (2000).
66. 3-induced PML or PML-retinoic acid receptor-α degradation. J. Exp. Med. 193, 1361-1372 (2001).
67. Shao, W. et al. Arsenic trioxide as an inducer of apoptosis and loss of PML-RARα protein in acute promyelocytic leukemia cells. J. Natl Cancer Inst. 90, 124-133 (1998).
68. Muller, S., Matunis, M. J. & Dejean, A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17, 61-70 (1998).
69. Zhu, J., Lallemand-Breitenbach, V. & de The, H. Pathways of retinoic acid- or arsenic trioxide-induced PML-RARα catabolism, role of oncogene degradation in disease remission. Oncogene 20, 7257-7265 (2001).
70. Hong, S. H., Yang, Z. & Privalsky, M. L. Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with its transcription factor partners, including the PML-retinoic acid receptor-α oncoprotein found in human acute promyelocytic leukemia. Mol. Cell. Biol. 21, 7172-7182 (2001).
71. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins. Proc. Natl Acad. Sci. USA 97, 10173-10178 (2000).
72. Jing, Y. et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 97, 264-269 (2001).
73. Au, W. Y. et al. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J. Haematol. 117, 130-132 (2002).
74. Koide, T. et al. Active repression of RAR signaling is required for head formation. Genes Dev. 15, 2111-2121 (2001).
75. Du, C. et al. Overexpression of wild-type retinoic acid receptor-α (RARα) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARα-fusion genes. Blood 94, 793-802 (1999).
76. Shao, W. et al. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation. Blood 89, 4282-4289 (1997).
77. Licht, J. D. et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85. 1083-1094 (1995).
78. Koken, M. H. M. et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF-RARα fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene 18, 1113-1118 (1999).
79. Jansen, J. H. et al. Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood 94, 39-45 (1999).
80. He, L. Z. et al. Myeloid leukemias in PLZF-RARα transgenic mice. Blood 90, 320a (1997).
81. Petti, M. et al. Complete remission through blast cell differentiation in PLZF-RARα positive acute promyelocytic leukemia: in vitro and in vivo studies. Blood 100, 1065-1067 (2002).
82. Fogal, V. et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19, 6185-6195 (2000).
83. Guo, A. et al. The function of PML in p53-dependent apoptosis. Nature Cell Biol. 2, 730-736 (2000).
84. Kroemer, G. & de Thé, H. Arsenic tnoxide, a novel mitochondriotoxic anti-cancer agent? J. Natl Cancer Inst. 91, 743-745 (1999).
85. Chou, W. C. et al. Arsenic inhibition of telomerase transcription leads to genetic instability. J. Clin. Invest. 108, 1541-1547 (2001).
86. Bazarbachi, A. et al. Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in HTLV-1 transformed cells. Blood 93, 278-283 (1999).
87. 3 combined with interferon-α induces both apoptosis and selective degradation of the Tax retroviral oncogene.
88. Ishov, A. M. et al. PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear tructure when modified by SUMO-1. J. Cell Biol. 147, 221-234 (1999).
89. Zhong, S. et al. Role of SUMO-1-modified PML in nuclear body formation. Blood 95, 2748-2752 (2000).
90. Salomoni, P. & Pandolfi, P. P. The role of PML in tumor suppression. Cell 108, 165-170 (2002).
91. Fabunmi, R. P., Wigley, W. C., Thomas, P. J. & DeMartino, G. N. Interferon-γ regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies. J. Cell Sci. 114, 29-36 (2001).
92. Baumann, C. T. et al. The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome. Mol. Endocrinol. 15, 485-600 (2001).
93. 2/M phase of the cell cycle, J. Cell Sci. 113, 4577-4585 (2000).
94. Lombard, D. B. & Guarente, L. Nijmegen breakage syndrome disease protein and MRE11 at PML nuclear bodies and meiotic telomeres. Cancer Res. 60, 2331-2334 (2000).
95. Bischof, O. et al. Regulation and localization of the bloom syndrome protein in response to DNA damage. J. Cell Biol. 153, 367-380 (2001).
96. Wu, G., Lee, W. H. & Chen, P. L. NBS1 and TRF1 colocalize at promyetocytic leukemia bodies during late S/G2 phases in immorlalized telomerase-negative cells. Implication of NBS1 in alternative lengthening of telomeres. J. Biol. Chem. 275, 30618-30622 (2000).
97. Muller, S., Hoege, C., Pyrowolakis, G. & Jentsch, S. SUMO, ubiquitin's mysterious cousin. Nature Rev. Mol. Cell Biol. 2, 202-210 (2001).
98. Mahajan, R. et al. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 108, 97-107 (1997).
99. Pichler, A. et al. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 108, 109-120 (2002).
100. Raymond, A. et al. The tripartite motif family identifies cell compartments. EMBO J. 20, 2140-2151 (2001).
101. Lehembre, F., Muller, S., Pandolfi, P. P. & Dejean, A. Regulation of Pax3 transcriptional activity by SUMO-1-modified PML Oncogene 20, 1-9 (2001).
102. Brown, D. et al. A PML RARα transgene initiates murine acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 94, 2551-2656 (1997).
103. He, L-Z et al. Acute leukemia with promyelocytic features in PML/RARα transgenic mice Proc. Natl Acad. Sci. USA 94, 5302-5307 (1997).
104. Merghoub, T., Gurrieri, C., Piazza, F. & Pandolfi, P. P. Modeling acute promyelocytic leukemia in the mouse: new insights in the pathogenesis of human leukemias. Blood Cells Mol. Dis. 27, 231-248 (2001).
105. Kogan, S. C. et al. Leukemia initiated by PML/RARα the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood 95, 1541-1550 (2000).
106. He, L. Z. et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108, 1321-1330 (2001).
107. Quenech'Du, N. et al. A sustained increase in the endogenous level of cAMP reduces the retinoid concentration required for APL cell maturation to near physiological levels. Leukemia 12, 1829-1833 (1998).
108. Gianni, M. et al. Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RARγ degradation and transactivation. EMBO J. 21, 3760-3769 (2002).
109. Recher, C. et al. In vitro and in vivo effectiveness of arsenic trioxide against murine T-cell prolymphocytic leukaemia. Br. J. Haematol. 117, 343-350 (2002).
110. Jing, Y., Xia, L. & Waxman, S. Targeted removal of PML-RARα protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. Blood 100, 1008-1013(2002).